# Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

> **NCT06712316** · PHASE2,PHASE3 · RECRUITING · sponsor: **BioNTech SE** · enrollment: 1260 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Pumitamig
- **DRUG:** Pembrolizumab
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT06712316
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-07
- **Primary completion:** 2029-02
- **Final completion:** 2030-03
- **Target enrollment:** 1260 (ESTIMATED)
- **Last updated:** 2026-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06712316

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06712316, "Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06712316. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*